We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

164 hedge funds and large institutions have $1.52B invested in Rocket Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $4.54M | Put options by funds: $1.03M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more capital invested

Capital invested by funds: $1.34B → $1.52B (+$177M)

13% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 54

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

1% more funds holding

Funds holding: 163 → 164 (+1)

3.73% less ownership

Funds ownership: 98.63% → 94.9% (-3.7%)

Holders
164
Holders Change
+1
Holders Change %
+0.61%
% of All Funds
2.57%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
18
Increased
61
Reduced
54
Closed
17
Calls
$4.54M
Puts
$1.03M
Net Calls
+$3.51M
Net Calls Change
+$371K

Top Buyers

1
Wellington Management Group
Wellington Management Group
Massachusetts
+$20.9M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$8.48M
3
PA
Perceptive Advisors
New York
+$6.07M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.09M
5
PHS
PFM Health Sciences
California
+$4.82M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$19.4M
2
State Street
State Street
Massachusetts
-$17M
3
LGM
Logos Global Management
California
-$13.1M
4
BlackRock
BlackRock
New York
-$6.69M
5
WP
Woodline Partners
California
-$5.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
26
Russell Investments Group
United Kingdom
$11.6M +$1.6M +79,192 +16%
Northern Trust
27
Northern Trust
Illinois
$11.4M +$539K +26,692 +5%
Morgan Stanley
28
Morgan Stanley
New York
$9.98M -$1.82M -89,902 -15%
Charles Schwab
29
Charles Schwab
California
$8.65M +$159K +7,851 +2%
GC
30
GMT Capital
Georgia
$8.59M -$1.5M -74,000 -15%
Bank of America
31
Bank of America
North Carolina
$8.58M -$3.74M -185,316 -30%
Assenagon Asset Management
32
Assenagon Asset Management
Luxembourg
$8.5M -$101K -5,017 -1%
Mirae Asset Global Investments
33
Mirae Asset Global Investments
South Korea
$7.08M +$1.04M +51,534 +17%
ACP
34
Acuta Capital Partners
California
$6.08M +$166K +8,194 +3%
WCM Investment Management
35
WCM Investment Management
California
$5.62M +$588K +29,123 +11%
Fidelity Investments
36
Fidelity Investments
Massachusetts
$5.33M +$708K +35,037 +15%
Qube Research & Technologies (QRT)
37
Qube Research & Technologies (QRT)
United Kingdom
$5.3M +$3.4M +168,207 +171%
LGM
38
Logos Global Management
California
$4.97M -$13.1M -650,000 -72%
Norges Bank
39
Norges Bank
Norway
$4.84M – – –
PHS
40
PFM Health Sciences
California
$4.74M +$4.82M +238,762 New
SFM
41
Sphera Funds Management
Israel
$4.69M – – –
Rafferty Asset Management
42
Rafferty Asset Management
New York
$4.63M -$1.34M -66,375 -22%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$4.54M -$3.16M -156,200 -41%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$3.98M -$113K -5,569 -3%
SAM
45
Sectoral Asset Management
Quebec, Canada
$3.79M – – –
Millennium Management
46
Millennium Management
New York
$3.56M +$3.62M +179,216 New
Nordea Investment Management
47
Nordea Investment Management
Sweden
$3.33M -$1.1M -54,294 -25%
Invesco
48
Invesco
Georgia
$3.12M +$2.35M +116,284 +285%
IBT
49
International Biotechnology Trust
United Kingdom
$3.09M +$1.88M +93,000 +148%
N
50
Nuveen
North Carolina
$3.07M +$24.7K +1,222 +0.8%
1
2
3 4 5

RCKT Hedge Fund Activity: Q2 2023 in Review

164 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2023, worth a combined $1.52B — up 13% from $1.34B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RCKT positions and 17 closed out — a net gain of 1 holder — while 61 added to existing stakes and 54 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $20.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.4M sold.

  • 164 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2023, up from 163 in Q1 2023.
  • Funds reported $1.52B of Rocket Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
  • 18 funds opened new Rocket Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +1 holder.
  • The largest Rocket Pharmaceuticals buyer in Q2 2023 was Wellington Management Group, an estimated $20.9M added.
  • The largest Rocket Pharmaceuticals seller in Q2 2023 was RA Capital Management, an estimated $19.4M sold.

Based on aggregated 13F filings for Q2 2023.